ERBB2 and breast cancer: In particular, we confirmed the prognostic significance of tumoral pCR as a biomarker to increase DFS and OS in HER2+ BC, independently of the lymph nodal response to NACT, as well as low post-NACT ki-67 expression and right-sided tumor.